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A subgroup of hemodialysis patients experience high serum
ferritin and low tansferrin saturation for reasons not clearly
understood. Here we determined the economic impact of
administering sodium ferric gluconate complex to patients
with serum ferritin levels higher than 500 ng/ml and a
transferrin saturation less than 25% based on the Dialysis
Patients Response to IV Iron with Elevated Ferritin (DRIVE)
study and its extension, DRIVE II. A cost effectiveness model
was developed, consistent with the DRIVE studies, using
decision analysis with a 12-week time horizon. The primary
effectiveness measure was the mean hemoglobin increase in
the intent to treat patient groups comparing epoetin with or
without sodium ferric gluconate complex. Costs were
computed using projected 2007 US Medicare
reimbursements for the treatments and for serious adverse
events, with the effectiveness factored by the increase in
hemoglobin. The net savings for sodium ferric gluconate
complex plus epoetin treatment was $1390 compared to
epoetin alone for each g/dl hemoglobin increase over 12
weeks of study. Sensitivity analyses were performed to test
the impact of change in the variables (using medians or
means and actual 2005 or projected 2007 Medicare
reimbursements) and these affirmed the robustness of the
model. Our study shows that treatment of patients with high
ferritin and low transferrin saturation levels, as defined in
DRIVE, with sodium ferric gluconate complex and epoetin
resulted in significant savings compared to epoetin alone.
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Anemia is a common complication in patients with chronic
kidney disease on dialysis. The estimated cost to Medicare for
the treatment of anemia exceeds $3 billion and these costs
continue to escalate as the average dose of erythropoietin and
iron increase. To address these concerns, the Centers for
Medicare and Medicaid Services have proposed a bundled
payment scheme for injectable medication costs and dialysis
services provided to Medicare beneficiaries with end-stage
renal disease.
In the wake of Correction of Hemoglobin and Outcomes
in Renal Insufficiency study1 and other studies of epoetin and
darbepoetin (erythropoiesis stimulating agents; ESA) show-
ing increased risk of cardiovascular events, thrombovascular
events, and death related to hemoglobin (Hb) targets greater
than 12 g/100 ml, the Food and Drug Administration added a
black box warning to ESA labels that recommended employ-
ing the lowest dose necessary, and stopping ESA when Hb
exceeded 12 g/100 ml.2 The National Kidney Foundation’s
guidelines were recently revised to recommend a more
conservative target Hb in the range of 11–12 g/100 ml.3
In September 2007, the Food and Drug Administration
Cardiovascular and Renal Drugs Advisory Committee and
the Drug Safety and Risk Management Advisory Committee
discussed the safety of ESA in patients with renal disease.4
Two key issues included the relationship of high ESA doses to
adverse outcomes independent of Hb, and the management
of patients who are ‘hyporesponders’ to ESA.4
Patients who are receiving very large doses of ESA account
for a disproportionate cost of anemia therapy. These patients
also have significantly worse outcomes, including a marked
increase in the risk of death.5,6 Thus, actions that reduce the
ESA dose may improve outcomes. Frequent characteristics
observed in patients with high ESA doses include high serum
ferritin and low transferrin saturation, which are thought to
reflect inflammatory blockade of iron.
Until the recently completed Dialysis Patients’ Response to
IV Iron with Elevated Ferritin (DRIVE) studies,7–9 it was
unclear if intravenous iron was efficacious in these patients.
DRIVE was a 6-week, prospective, multicenter, randomized
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trial in anemic hemodialysis patients with serum ferritin level
4500 ng/ml and a TSATo25%, despite receiving more than
225 IU/kg per week or more than 22,500 IU per week of
epoetin alfa (Epogen, Amgen, Thousand Oaks, CA, USA).
Those patients randomized to receive 1 g of sodium ferric
gluconate complex (SFGC; Ferrlecit, Watson Laboratories,
Morristown, NJ, USA) showed a significantly greater increase
in Hb compared to no iron therapy.7,8 The 6-week follow-up
observational extension study (DRIVE II), during which
there were no restrictions on epoetin or intravenous iron
dosing, revealed persistently higher Hb and significant
reductions in ESA use in the iron-treated group, compared
to the group not initially receiving iron.9
The combined findings from the DRIVE studies suggest
that administering intravenous iron to patients with high
ferritin and low TSAT improves the therapeutic efficiency of
anemia treatment and reduces epoetin costs. The objective of
our analysis was to develop an economic model to estimate
the economic impact of DRIVE and DRIVE-II findings using
decision analysis. Secondarily, we explored the impact of
model findings to the Medicare program using data from the
2004 United States Renal Data System.
RESULTS
The economic model was based on data from the 129
patients in the DRIVE intent-to-treat population. The
average age was about 60 (58.7±15.2 and 61.2±13.0 years
in the epoetin only and SFGCþ epoetin groups, respec-
tively), and the groups were roughly 50% women (56.9 and
42.2% in the epoetin only and SFGCþ epoetin groups,
respectively). There were no significant differences in any of
the baseline demographic or biochemical characteristics
between the two groups. Additional detailed information
about the study populations has been published pre-
viously.7–9
Base case economic model
Our analysis of DRIVE and DRIVE-II data indicated that the
total cost per patient receiving SFGCþ epoetin was $3675 per
g/100 ml increase in Hb. The total cost per patient receiving
epoetin alone was $5065 per g/100 ml increase in Hb. This
represents a net savings of $1390 per g/100 ml increase in Hb
over a 12-week period. The costs associated with each
variable in this model are presented in Table 1.
Sensitivity analyses
We performed sensitivity analyses to test the robustness of
our observations. When the Medicare allowable costs for the
two medications were replaced by the 25th and 85th
percentile national reimbursement rates, the increased cost
of SFGC made the cost of the SFGCþ epoetin therapy greater
than that of the epoetin therapy alone. In this case, the
incremental cost-effectiveness ratio, or the additional cost for
each additional g/100 ml increase in Hb, was $288.95 and
$1553.29 at the 25th and 85th percentiles, respectively, for
SFGCþ epoetin versus epoetin alone. If all of the other
model assumptions and costs remain equal, the cost of SFGC
would have to increase to $894.00 per gram to shift the
outcome from dominance of SFGCþ epoetin to a cost-
effectiveness trade-off. The model was robust to all other
univariate sensitivity analyses described in the Materials and
Methods section. The variables used in each of the univariate
sensitivity analyses are reported in Table 1, and results of this
analysis are described in detail in Table 2.
Table 1 | Values used in the base case model, and in each univariate sensitivity analysis
Model version
Modified adverse event
costs Modified medication costs Modified treatment efficacies
Model Arm Variable Base model
Modified
study
population
2005 actual
hospitalization
costs
Fixed
hospital
cost per
day
Median
medication
usage
25th
percentile
medication
costs
85th
percentile
medication
costs
Median
treatment
efficacy
Treatment
efficacy1
standard
deviation
Treatment
efficacy+1
standard
deviation
SFGC+epoetin Cost of SFGC $499.13 $499.82 $499.13 $499.13 $457.92 $1151.04 $1988.16 $499.13 $499.13 $499.13
Cost of epoetin $4031.78 $4144.26 $4031.78 $4031.78 $3554.73 $7346.23 $12,963.93 $4031.78 $4031.78 $4031.78
Cost of adverse
events
$6455.66 $6742.66 $7335.16 $10,042.69 $6455.66 $6456.66 $6457.66 $6455.66 $6455.66 $6455.66
Probability of
adverse events
26.60% 25.90% 26.60% 26.60% 26.60% 26.60% 26.60% 26.60% 26.60% 26.60%
Treatment
efficacy
1.7 g/100 ml 1.8 1.7 g/100 ml 1.7 g/100 ml 1.7 g/100 ml 1.7 g/100 ml 1.7 g/100 ml 1.5 0.3 3.1
Epoetin alone Cost of SFGC $50.28 $48.20 $50.28 $50.28 $0.00 $115.96 $200.29 $50.28 $50.28 $50.28
Cost of epoetin $4248.92 $4331.55 $4248.92 $4248.92 $3892.94 $7741.54 $13,662.12 $4248.92 $4248.92 $4248.92
Cost of adverse
events
$6858.47 $6980.93 $7314.61 $14,346.70 $6858.47 $6859.47 $6860.47 $6858.47 $6858.47 $6858.47
Probability of
adverse events
33.80% 33.30% 33.80% 33.80% 33.80% 33.80% 33.80% 33.80% 33.80% 33.80%
Treatment
efficacy
1.3 g/100 ml 1.4 1.3 g/100 ml 1.3 g/100 ml 1.3 g/100 ml 1.3 g/100 ml 1.3 g/100 ml 1.3 0.3 2.9
SFGC, sodium ferric gluconate complex; shaded areas indicate model inputs that changed under each univariate sensitivity analysis.
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The results of the probabilistic sensitivity analysis also
demonstrated that the combination of SFGCþ epoetin
tended to be the more cost-effective option as compared to
epoetin alone. The scatter plot in Figure 1 illustrates the
extent of the variability in the model, with the origin
representing the relative cost and efficacy of epoetin alone
and each point representing the comparative cost effective-
ness of SFGCþ epoetin in combination based on an outcome
from the Monte Carlo simulation. Analysis of the results do
show that 32.53% of the points are in the lower right hand
portion of the graph, demonstrating that SFGCþ epoetin in
combination may be less costly and more effective than
epoetin alone, versus the 18.49% of points in the upper left
corner demonstrating that epoetin alone may be less costly
and more effective. The remaining 48.98% of points are in
the two quadrants where a decision has to be made regarding
an increased cost for increased efficacy. In situations where
one treatment option is both more effective and less costly
that treatment may be referred to as dominant.
DISCUSSION
The principal finding of our study is that in a population of
dialysis patients characterized by a high serum ferritin
concentration and low transferrin saturation, the adminis-
tration of parenteral iron was cost effective. Our base
case analysis indicates that administering 1 g of SFGC results
in a $1390 saving per gram per deciliter of Hb increased
over a 12-week period. Thorough sensitivity analyses
were completed to validate this result. As the DRIVE studies
provided clinical and hospitalization inputs but were not
designed to capture costs, a decision analysis model was
necessary.
Table 2 | Results of each sensitivity analysis, compared to base case
Difference between epoetin alone
and SFGC+epoetin Average cost effectiveness ratio
Model Version
Incremental
change in
hemoglobin
Incremental
change in cost
SFGC+epoetin arm
(cost per g/100 ml
increase in Hb)
Epoetin alone arm
(cost per g/100 ml
increase in Hb) ICERa
Base case 0.4 g/100 ml 335.96 $3675.36 $5064.68 SFGC+epoetin
dominates epoetin alone
Modified study population 0.4 g/100 ml 594.19 $3523.46 $5064.67 SFGC+epoetin
dominates epoetin alone
Modified hospitalization costs (used 2005
actual reimbursements)
0.4 g/100 ml 256.19 $3812.98 $5183.27 SFGC+epoetin
dominates epoetin alone
Employed fixed hospital cost per day 0.4 g/100 ml 1912.83 $4236.63 $7011.61 SFGC+epoetin
dominates epoetin alone
Employed median medication usage 0.4 g/100 ml 481.24 $3370.50 $4777.77 SFGC+epoetin
dominates epoetin alone
Applied 25th percentile medication costs 0.4 g/100 ml 115.58 $7768.38 $6008.52 $288.95 per additional g/
100 ml increase in Hb
Applied 85th percentile medication costs 0.4 g/100 ml 621.32 $12,344.60 $9805.47 $1553.29 per additional
g/100 ml increase in Hb
Used median treatment efficacy 0.2 g/100 ml 335.96 $4165.41 $5064.67 SFGC+epoetin
dominates epoetin alone
Used treatment efficacy1 standard
deviation
0.6 g/100 ml 335.96 $20,827.05 $21,946.92b SFGC+epoetin
dominates epoetin alone
Treatment efficacy+1 standard deviation 0.2 g/100 ml 335.96 $2015.52 $2270.37 SFGC+epoetin
dominates epoetin alone
SFGC, sodium ferric gluconate complex; ICER, incremental cost-effectiveness (utility) ratio; Hb, hemoglobin; shaded line indicates the base case.
aIf one treatment option is both less costly, and more effective, the ICER will be calculated as a negative number. When this happens, it is most appropriate to simply report
that one treatment option dominates the other.
bBecause the efficacy was negative in this analysis, the CE ratio was also negative.
This quadrant represents
points indicating that SFGC
+epoetin is less costly and
more effective than epoetin
alone (32.5%)
This quadrant represents
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This quadrant
represents points
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Figure 1 | Results of the probabilistic sensitivity analysis,
showing the incremental cost-effectiveness scatter plot of
SFGCþ epoetin versus epoetin alone based on 1 million
random iterations of the cost-effectiveness model (%
indicates the proportion of points in each quadrant).
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Findings are of significant interest given the recent
attention to the cost of anemia management in dialysis
patients.10,11 Use of intravenous iron in patients with high
ferritin and low TSAT is now a proven strategy to improve
the efficacy and reduce the cost of anemia treatment in the
subset of patients accounting for the greatest expense. A
limited review of United States Renal Data System data was
performed to identify the extent of the dialysis population
that might be influenced by the findings of the DRIVE
studies and this economic analysis. This review found that,
based on the 2004 survey of hemodialysis patients, 8.7% of
patients had Hb levels of less than 11 g/100 ml, TSAT less
than or equal to 25%, and ferritin levels greater than 500 ng/
ml during one or more of the 3 months surveyed. When
looking at only the patients with Hb less than 11 g/100 ml,
19.3% had a TSAT less than or equal to 25% and a ferritin
level greater than 500 ng/ml at any given point of follow-up.
These data suggest that our economic analysis of DRIVE may
apply to a significant number of dialysis patients, and though
our analysis does not reflect long-term cost effectiveness
beyond 12 weeks, may have broad financial implications for
the Medicare program. Furthermore, as hospitalizations
result in missed outpatient dialysis sessions, our findings
are also relevant to facilities providing these services. The
total number of hospital days among the SFGCþ epoetin
group was 119, with the same number being 228 in the
epoetin alone group. This translates to an estimated 51
outpatient dialysis sessions lost in the SFGCþ epoetin group
and 90 outpatient dialysis sessions lost in the epoetin group
(assuming three sessions per patient per week). Assuming the
average reimbursement for dialysis services plus separately
billable items to be $240 per session,12 reimbursements to
dialysis facilities for the epoetin only group would be
approximately $9300 less than in the SFGCþ epoetin group.
Several aspects of our study and analysis may have actually
led to an underestimation of the cost savings of
SFGCþ epoetin. First, epoetin doses were flexible only
during DRIVE II (the last 6 weeks of our model’s time
horizon), thereby limiting the opportunity to observe a long-
term difference in epoetin dose between the groups; and
second, epoetin dosages were not available during patient
hospitalizations. As the rate and duration of hospitalizations
was slightly higher in the epoetin only group and patients
dropped out of the study if hospitalized because of a serious
adverse event (SAE) (the rate of which was slightly higher for
the epoetin only group), we surmise that the true amount of
epoetin administered to both groups exceeds our available
data and is higher for the epoetin alone than the
SFGCþ epoetin group.
A second area where costs were likely underestimated is
hospitalizations. Diagnostic-related groups were used to
estimate the cost of hospitalizations in each group, but may
not have been able to account for the complicated nature of
treatment for patients in this population. This underestimation
of hospital costs was addressed through two of the univariate
sensitivity analyses, which indicated that increased costs were
not likely to change our conclusions. It should be noted that
the epoetin alone group experienced more hospitalizations,
thereby underscoring the conservative nature of the model.
SFGCþ epoetin persisted as the more cost-effective
treatment through all but one univariate sensitivity analysis,
where we tested the potential impact of changing one
assumption at a time. In one of these sensitivity analyses,
epoetin only became the less costly option, although the
combination treatment was still more efficacious. That
scenario assumed medication reimbursement rates that were
higher than those in the base case model, the 25th and 85th
percentile of national reimbursement rates for iron and
epoetin were tested; these rates are significantly higher than
Medicare reimbursement even at the 25th percentile. This
situation better simulates reimbursement by private payers
than that encountered in Medicare. As private payers cover a
small percentage of US dialysis services, this scenario should
not be the focus of societal decision making. Rather, our base
case, which employs Medicare allowable costs as the basis of
reimbursement, is applicable to decisions made regarding the
majority of Americans receiving dialysis.
The probabilistic sensitivity analyses we presented suggest
that SFGCþ epoetin may not always be cost effective when
one accounts for the uncertainty surrounding our model
inputs. This is not surprising when one considers the extent
of variability observed in the DRIVE studies due to the small
sample size and short follow-up period. Had the studies
included a larger sample and if DRIVE II had been extended
beyond 6 weeks, we believe that variability around the inputs
would have lessened and the cumulative dose difference in
epoetin between the groups would have widened—resulting
in a greater probability that the SFGCþ epoetin treatment
strategy is cost effective.
Other issues surround the length of follow-up time in the
DRIVE studies. On the basis of the original study design, we
examined the cost of hospitalizations and anemia therapy
over only a 12-week period. Conceivably, longer follow-up
could have shown alterations in the overall cost of therapy
and hospitalization trends, altering the outcome of the
economic analysis.
This study has both limitations and strengths. A
potentially important limitation is that it is a post hoc
analysis of the DRIVE study and may not be generalizible to
clinical practice. Although it is true that the model was based
on a protocol-driven scenario, the care of patients was largely
at the discretion of the local care givers. The strength of this
design was that outcomes and adverse events were carefully
monitored. The detailed narratives provided for SAEs were
quite instrumental in characterizing their nature and cost.
Additionally, the outcome measured in this model was the
absolute change in Hb level, rather than the percent of
patients reaching a predetermined goal because there is still
controversy surrounding the ideal Hb target. Another
limitation is that we included only SAEs in our analysis,
which by definition included all hospitalizations. Although
mild and moderate events were reported during the studies,
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these events were quite varied and frequently unrelated to
treatment. Furthermore, we postulated that the cost attribu-
table to these events would be minor from a Medicare
perspective. An important strength was our use of probabil-
istic sensitivity analysis. This method enabled us to
simultaneously test the uncertainty around all model inputs,
establishing a level of confidence in terms of where the true
cost effectiveness of SFGCþ epoetin lies.
In summary, this cost-effectiveness analysis of DRIVE
study data suggests that administering 1 g of SFGC to
patients with high ferritin and low TSAT results in cost
savings when the Medicare perspective is employed. Over the
12-week period, patients receiving the combination of
SFGCþ epoetin used 23,273 fewer units of epoetin and
experienced a greater increase in Hb (1.7 versus 1.3 g/100 ml).
When incorporated into a decision-analytic model,
SFGCþ epoetin treatment was estimated to result in a
savings of $1390 per g/100 ml of Hb increase, which may be
conservative due to the fixed doses of epoetin required during
the first 6 weeks of DRIVE. Our findings suggest that
administering SFGC to this subset of anemic hemodialysis
patients represents one potential strategy for reducing
Medicare treatment costs. Application of our model to a
population-level database is worthwhile to determine if
findings hold true in actual practice.
MATERIALS AND METHODS
Base case model
Study data, design, and population. This cost-effectiveness
study is based on a decision analysis model of data from the DRIVE
study and the observational follow-up study DRIVE II. These
studies examined the effectiveness of treatment with a combination
of IV SFGCþ epoetin as compared to epoetin alone. Details of the
DRIVE studies have been described by Coyne et al.7 Published and
unpublished aggregate data as well as adverse event narratives were
available for inclusion in the economic model. Cost data were
estimated based on published sources of Medicare reimbursement
rates for dialysis services.13,14 Patients included in this study were
anemic (Hb concentrations o11 g/100 ml) with low TSAT (p25%)
and high ferritin concentrations (500–1200 ng/ml), already receiving
more than 225 IU/kg per week or more than 22,500 IU per week of
epoetin and were undergoing hemodialysis. Assumptions detailed
herein are summarized in Table 3.
The population for the base case economic model is the DRIVE
intent-to-treat population that consists of 129 patients. Demo-
graphic characteristics of these patients were described previously.7
During the first 6 weeks of the study, patients were randomized on a
1:1 basis to each treatment group. Both treatment groups received a
25% increase in their baseline epoetin dose, whereas the
SFGCþ epoetin group also received 1 g of IV SFGC. During the 6
weeks of the DRIVE-II phase, treatment in both study arms was
adjusted as appropriate. Eleven study participants dropped out due
to adverse events with the last observations carried forward for these
patients.
The model is based on the best practices issued by the
International Society for Pharmacoeconomics and Outcomes
Research task force on good research practices in modeling studies.15
Table 3 | Summary of assumptions used in the base case
model
1. Adverse event costs
K Cost of adverse events was calculated based on hospitalizations
due to the serious adverse events reported during the DRIVE
studies.
K DRG codes were assigned to each of these hospitalizations based
on the primary reason for the hospitalization as described in the
provided narratives.
K If patients were re-hospitalized within 30 days for issues related to
the original hospitalization, the two hospitalizations were
considered to be the same.
K Individual hospitalization costs were based on estimated Medicare
reimbursements for 2007. The average cost of hospitalizations in
each treatment group was then calculated
2. Medication costs
K The medication costs for each treatment were estimated by
multiplying the mean utilization over the 12-week study period by
the estimated Medicare allowable costs
3. Adverse event probabilities
K The probability of hospitalization due to adverse events was
calculated as the total number of hospitalizations due to serious
adverse events divided by the total number of patients in each
treatment.
4. Treatment efficacies
K The efficacies for each treatment group are defined as the mean
increase in hemoglobin from baseline to week 12 as reported in the
DRIVE study findings
DRIVE, Dialysis Patients Response to IV Iron with Elevated Ferritin; DRG, diagnosis-
related group.
Effectiveness
of epoetin
alone
Effectiveness
of SFGC and
epoetin
EffectivenessCosts
Cost of SFGC+
cost of epoetin+
cost of an adverse event
Cost of SFGC+
cost of epoetin
Cost of epoetin+
cost of an adverse event
Cost of epoetin
Patients with no
serious adverse event
Patients suffering a
serious adverse event
Patients with no
serious adverse event
Patients suffering a
serious adverse eventPatients
receiving SFGC
and epoetin
Patients
receiving
epoetin alone
Anemic patients with low
TSAT and high ferritin levels
Figure 2 | Decision tree framework, showing DRIVE study arms, which served as the basis for the economic model.
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Branches of the decision tree framework (Figure 2) illustrate the two
DRIVE study arms. Each branch then accounted for the occurrence
of SAEs observed during the study. The costs and effects associated
with each pathway are considered in the payoff at each terminal
node. Because Medicare is the major payer for dialysis and related
services, all costs in this model were calculated using the Medicare
payer perspective. The time horizon of the tree was 12 weeks,
consistent with the combined duration of the DRIVE and DRIVE-II
studies. The decision tree was constructed using TreeAge Pro 2006
Healthcare (Williamstown, MA, USA).
Medication costs. The medication costs for each treatment
were estimated by multiplying the mean utilization in each
treatment group over the 12-week study period by the 2007
estimated Medicare allowable costs.13 The base cost of epoetin in
this model is $9.33 per 1000 IU; the base cost of SFGC is $4.77 per
12.5 mg. Mean epoetin usage in the SFGCþ epoetin group and the
epoetin only group was 432,131 and 455,404 IU, respectively, over 12
weeks. The mean SFGC use in the SFGCþ epoetin group and the
epoetin only group was 1308 and 132 mg, respectively, over 12
weeks. Therefore, the mean medication cost for the SFGCþ epoetin
Table 4 | Serious adverse events observed in the DRIVE studies, and cost
Treatment
Adverse event
description
Assigned
DRG code Assigned DRG description
Estimated 2007 reimbursement for
this DRG ($US)
SFGC+
epoetin
Syncope 141 Syncope and collapse with CC 3720.45
Abdominal pain NOS 463 Signs and symptoms with CC 3491.67
Endocarditis NOS 126 Acute and subacute endocarditis 12,986.21
Implant infection 120 Other circulatory system O.R. procedures 11,777.93
Kidney transplant rejection 442 Other O.R. procedures for injuries with cc 12,446.22
Cardiac arrest 121 Circulatory disorders with acute myocardial
infarction and major complications, discharged alive
7883.34
Hypertension NOS 134 Hypertension 3020.95
Cardiac failure congestive 127 Heart failure and shock 5114.58
Skin and subcutaneous
tissue abscess
277 Cellulitis, age 417 with CC 4365.81
Clotted tesio catheter 317 Admission for renal dialysis 3935.08
Gangrene 130 Peripheral vascular disorders with CC 4736.05
Fluid overload 317 Admission for renal dialysis 3935.08
Pleural effusion 85 Pleural effusion with CC 6076.52
Coagulation time NOS,
prolonged
397 Coagulation disorders 6477.98
Implant infection 120 Other circulatory system O.R. procedures 11,777.93
Congestive cardiac failure
aggravated
317 Admission for renal dialysis 3935.08
Hypoglycemia NOS 296 Nutritional and miscellaneous metabolic disorders, age 417
with CC
4065.33
Epoetin
only
Peritonitis 572 Major gastrointestinal disorders and peritoneal infections 6525.79
Gastric erosions 182 Esophagitis, gastroenteritis and miscellaneous digestive
disorders, age 417 with CC
3831.67
Nodal arrhythmia 138 Cardiac arrhythmia and conduction disorders with CC 4079.47
Sepsis NOS 120 Other circulatory system O.R. procedures 11,777.93
Pancreatitis acute 204 Disorders of pancreas except malignancy 5360.43
Cerebrovascular accident 14 Intracranial hemorrhage or cerebral infarction 5907.25
Cardiac failure, congestive 127 Heart failure and shock 5114.58
Pneumonia NOS 89 Simple pneumonia and pleurisy, age 417 with CC 5061.41
Pneumonia staphylococcal 565 Respiratory system diagnosis with ventilator support o96
hours
25,509.01
Pulmonary edema 87 Pulmonary edema and respiratory failure 6748.71
Colitis ischemic 182 Esophagitis, gastroenteritis and miscellaneous digestive
disorders, age 417 with CC
3831.67
Cardiac failure, congestive 127 Heart failure and shock 5114.58
Dyspnea NOS 317 Admission for renal dialysis 3935.08
Cellulitis 277 Cellulitis, age 417 with CC 4365.81
Skin and subcutaneous
tissue abcess
277 Cellulitis, age 417 with CC 4365.81
Failure to thrive 172 Digestive malignancy with CC 6965.78
Sepsis NOS 576 Septicemia without ventilator support, 96+ hours; age 417 7781.87
Blood culture, positive 576 Septicemia without ventilator support, 96+ hours; age 417 7781.87
Cellulitis 277 Cellulitis, age 417 with CC 4365.81
Pulmonary edema NOS 87 Pulmonary edema and respiratory failure 6748.71
Sepsis NOS 120 Other circulatory system O.R. procedures 11,777.93
Fluid overload 317 Admission for renal dialysis 3935.08
DRG, diagnosis-related group; SFGC, sodium ferric gluconate complex; NOS, nitric oxide synthase; CC, complicating condition; OR, operating room.
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group was $4530.91, and the mean medication cost for the epoetin
alone group was $4299.20.
Adverse event costs and probabilities. The cost of adverse
events was calculated based on hospitalizations due to the SAE
reported during the DRIVE studies. Diagnostic-related group codes
were assigned to each of these hospitalizations based on the primary
reason for the hospitalization as described in the provided
narratives. If patients were rehospitalized within 30 days for issues
related to the original hospitalization, the two hospitalizations were
considered to be the same. Individual hospitalization costs were
based on estimated Medicare reimbursements for 200714 for the
diagnostic-related groups pertaining to the events experienced. The
average cost of hospitalizations in each treatment group was then
calculated. The average cost for an SAE in the SFGCþ epoetin group
was $6455.66, whereas the average cost for an SAE in the epoetin
alone group was $6858.47. Diagnostic-relaated group codes and
costs for each severe adverse event are described in Table 4.
The probability of hospitalization due to adverse events was
calculated as the total number of hospitalizations due to SAEs
divided by the total number of patients in each treatment group.
There were 17 hospitalizations in the SFGCþ epoetin group (64
total patients), and 22 in the epoetin alone group (65 total patients).
Therefore, probability of hospitalization due to a SAE in the
SFGCþ epoetin group was 26.6%, whereas the probability in the
epoetin alone group was 33.8%.
Treatment efficacies. The efficacies for each treatment group
are defined as the mean increase in Hb from baseline to week 12.
The mean increase in Hb for the SFGCþ epoetin group and the
epoetin alone group was 1.7 and 1.3 g/100 ml, respectively.
Sensitivity analyses
Univariate sensitivity analyses were conducted to determine the
impact of uncertainty about the definitions and assumptions
described above on the outcomes of this study. Probabilistic
sensitivity analysis was conducted as well. These analyses are
described below.
Univariate sensitivity analyses
Modified study population. The base case model is based on
results in the intent-to-treat population for DRIVE I. Because some
patients dropped out for various reasons between DRIVEs I and II,
the model was also repeated using data from the DRIVE-II safety
population.
Modified adverse event costs. In the base case model, the cost
of adverse events was calculated based on hospitalizations due to the
SAEs reported during the DRIVE studies, and resulting Medicare
reimbursements for these events.13 To test the validity of our costing
methods, two sensitivity analyses were conducted. First, actual
Medicare reimbursements from 2005, as reported in the MEDPAR
data16 were used to define the average cost of hospitalizations due to
adverse events. Next, a set cost of $1434.67 per day of hospitalization
(based on average reimbursement per day of all hospitalizations for
Medicare patients) was used to calculate the cost of SAEs.
Modified medication costs. In the base case model, the
medication costs for each treatment were estimated by multiplying
the mean utilization over the 12-week study period by the estimated
Medicare allowable costs.13 To determine the validity of this method,
the median utilization over 12 weeks was used in estimating the
costs of treatment, to determine if the distribution of utilization had
any impact on the model findings. Additionally, a range of costs
based on national reimbursement levels for the SFGCþ epoetin was
tested to determine if this influences the outcome of the model. The
range included reimbursement amounts from the 25th to 85th
percentile nationally.13
Treatment efficacies. Treatment efficacies for each group are
defined as the mean increase in Hb from baseline to week 12 as
reported in the DRIVE study findings. The validity of this definition
was tested by increasing and decreasing the treatment efficacies by
one standard deviation, as well as running the model based on the
median efficacy values reported in the DRIVE clinical trials.7–9
Probabilistic sensitivity analysis
The probabilistic sensitivity analysis consisted of a Monte Carlo
simulation model. The probabilistic sensitivity analysis was
conducted based on estimated distributions for each variable in
the model, with each distribution based on the mean and standard
deviation of all probabilities, costs, and effects. If the standard
deviation of a variable was not available, it was assumed to be 10%
of the mean. The simulation consisted of 1 million random
iterations with the goal of determining the likelihood that SFGC
plus epoetin is more cost effective than epoetin alone (e.g., is the
dominant choice).
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